|
DE1266763B
(de)
*
|
1965-07-27 |
1968-04-25 |
Kalle Ag |
Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten
|
|
EP0924209B1
(en)
|
1997-12-19 |
2003-05-02 |
Eli Lilly And Company |
Hypoglycemic imidazoline compounds
|
|
GB9816263D0
(en)
*
|
1998-07-24 |
1998-09-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB9905010D0
(en)
|
1999-03-04 |
1999-04-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU7514700A
(en)
|
1999-09-07 |
2001-04-10 |
Syngenta Participations Ag |
Cyanopiperidines
|
|
FR2801585B1
(fr)
|
1999-11-25 |
2002-02-15 |
Fournier Ind & Sante |
Nouveaux antagonistes des recepteurs de l'ii-8
|
|
GB0003397D0
(en)
|
2000-02-14 |
2000-04-05 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2002211828A1
(en)
|
2000-10-02 |
2002-04-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
FR2824826B1
(fr)
|
2001-05-17 |
2003-11-07 |
Fournier Lab Sa |
Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
|
|
FR2824827B1
(fr)
|
2001-05-17 |
2004-02-13 |
Fournier Lab Sa |
Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
|
|
ES2234451T1
(es)
|
2001-11-14 |
2005-07-01 |
Teva Pharmaceutical Industries Ltd. |
Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
|
|
WO2003104180A1
(en)
|
2002-06-05 |
2003-12-18 |
Natco Pharma Limited |
Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
JP2007504221A
(ja)
|
2003-09-03 |
2007-03-01 |
ガラパゴス・エヌブイ |
新規な４−ピペリジンカルボキシアミドおよび５ｈｔ２ａ受容体関連障害に対する薬剤の製造のためのその使用
|
|
BRPI0507657A
(pt)
|
2004-03-03 |
2007-07-10 |
Lilly Co Eli |
composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
|
|
WO2007061763A2
(en)
|
2005-11-22 |
2007-05-31 |
Merck & Co., Inc. |
Indole orexin receptor antagonists
|
|
PT2118074E
(pt)
|
2007-02-01 |
2014-03-20 |
Resverlogix Corp |
Compostos para a prevenção e tratamento de doenças cardiovasculares
|
|
DK2178870T3
(en)
|
2007-08-17 |
2018-10-22 |
Lg Chemical Ltd |
INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE
|
|
JP2011525915A
(ja)
*
|
2008-06-26 |
2011-09-29 |
アムジエン・インコーポレーテツド |
キナーゼ阻害薬としてのアルキニルアルコール類
|
|
CN105254557A
(zh)
|
2009-05-29 |
2016-01-20 |
拉夸里亚创药株式会社 |
作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
|
|
WO2012025155A1
(en)
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
|
US10130632B2
(en)
|
2012-11-27 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
|
EP3049405A4
(en)
|
2013-09-26 |
2017-03-08 |
Pharmakea Inc. |
Autotaxin inhibitor compounds
|
|
EP3461812B1
(en)
|
2014-03-27 |
2021-10-13 |
Academisch Medisch Centrum |
N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
|
|
EP3186225A4
(en)
|
2014-08-27 |
2018-02-28 |
The Governing Council of the University of Toronto |
Cannabinoid type 1 receptor modulators
|
|
US10654838B2
(en)
|
2014-10-08 |
2020-05-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Aminopyridine compounds useful as inhibitors of protein prenylation
|
|
HUE053705T2
(hu)
|
2015-08-27 |
2021-07-28 |
Pfizer |
Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
|
|
CN106008477B
(zh)
*
|
2016-06-02 |
2019-02-26 |
苏州大学 |
3-(2-芳基-1h-吲哚-3-基)-4-羟基呋喃-2(5h)-酮及其合成方法
|
|
EP3787669A4
(en)
|
2018-04-30 |
2022-03-30 |
The Trustees of Indiana University |
COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
|
|
IL278785B2
(en)
|
2018-05-22 |
2025-03-01 |
Ionis Pharmaceuticals Inc |
Modulators of apol1 expression
|
|
US11618746B2
(en)
*
|
2018-12-17 |
2023-04-04 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of APOL1 and methods of using same
|
|
WO2021154997A1
(en)
|
2020-01-29 |
2021-08-05 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
US20210246121A1
(en)
|
2020-02-04 |
2021-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitor and methods of using same
|
|
IL296035A
(en)
|
2020-03-06 |
2022-10-01 |
Vertex Pharma |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
|
JP2023524563A
(ja)
|
2020-05-07 |
2023-06-12 |
ラムバム メド－テック リミテッド |
Ａｐｏｌ１－関連疾患の治療に使用するための組成物
|
|
CA3185604A1
(en)
|
2020-06-12 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and use of the same
|
|
CN115867543A
(zh)
|
2020-06-12 |
2023-03-28 |
弗特克斯药品有限公司 |
Apol1抑制剂的固体形式及其使用方法
|
|
CN115867532A
(zh)
|
2020-06-12 |
2023-03-28 |
弗特克斯药品有限公司 |
Apol1的抑制剂及其用途
|
|
CN116547287B
(zh)
|
2020-08-26 |
2025-09-26 |
弗特克斯药品有限公司 |
Apol1的抑制剂及其使用方法
|
|
US20230119114A1
(en)
|
2021-08-26 |
2023-04-20 |
Vertex Pharmaceuticals Incorporated |
Solid forms of apol1 inhibitors and methods of using same
|
|
EP4440697A1
(en)
|
2021-11-30 |
2024-10-09 |
Vertex Pharmaceuticals Incorporated |
Spirocyclic inhibitors of apol1 and methods of using same
|
|
US12612379B2
(en)
|
2021-11-30 |
2026-04-28 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of APOL1 and methods of using same
|
|
CN119212986A
(zh)
|
2022-02-08 |
2024-12-27 |
弗特克斯药品有限公司 |
作为apol1的抑制剂的螺哌啶衍生物及其使用方法
|
|
CA3251050A1
(en)
|
2022-02-08 |
2023-08-17 |
Vertex Pharmaceuticals Incorporated |
2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES USED AS APOL1 INHIBITORS AND THEIR METHODS OF USE
|
|
AU2023219516A1
(en)
|
2022-02-08 |
2024-08-22 |
Vertex Pharmaceuticals Incorporated |
2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
|
|
EP4476228A1
(en)
|
2022-02-08 |
2024-12-18 |
Vertex Pharmaceuticals Incorporated |
4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
|